Defining response profiles after alemtuzumab : Rare paradoxical disease exacerbation. / Wiendl, Heinz; Calabresi, Peter A.; Meuth, Sven G.In: Neurology, Vol. 90, No. 7, 13.02.2018, p. 309-311.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Defining response profiles after alemtuzumab
T2 - Rare paradoxical disease exacerbation
AU - Wiendl, Heinz
AU - Calabresi, Peter A.
AU - Meuth, Sven G.
N1 - Funding Information: H.W.’s and S.G.M.’s work is supported by the German Research Foundation (DFG) and the Ministry of Education and Research (BMBF, the German Competence Network MK, KKNMS). Funding Information: Heinz Wiendl receives honoraria for acting as a member of Scientific Advisory Boards and as consultant for Biogen, Evgen, MedDay Pharmaceuticals, Merck Serono, Novartis, Roche Pharma AG, and Sanofi-Genzyme, as well as speaker honoraria and travel support from Alexion, Biogen, Cog-nomed, F. Hoffmann-La Roche Ltd., Gemeinnützige Hertie-Stiftung, Merck Serono, Novartis, Roche Pharma AG, Sanofi-Genzyme, TEVA, and WebMD Global. Prof. Wiendl acts as a paid consultant for AbbVie, Actelion, Biogen, IGES, Novartis, Roche, Sanofi-Genzyme, and the Swiss Multiple Sclerosis Society. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgesellschaft (DFG), Else Kröner Fresenius Foundation, Fresenius Foundation, Hertie Foundation, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster and RE Children’s Foundation, Biogen GmbH, GlaxoSmithKline GmbH, Roche Pharma AG, and Sanofi-Genzyme. Peter Calabresi has received consulting fees from Biogen Idec and DiSARM Therapeutics. He is PI on grants to Johns Hopkins University from Annexon, MedImmune, Genzyme, Novartis, and Biogen. Sven G. Meuth has received honoraria for lecturing, travel expenses for attending meetings, and financial research support from Almirall, Bayer Health Care, Biogen, Diamed, Genzyme, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, and Teva. Go to Neurology. org/N for full disclosures.
PY - 2018/2/13
Y1 - 2018/2/13
UR - http://www.scopus.com/inward/record.url?scp=85050015295&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050015295&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000004969
DO - 10.1212/WNL.0000000000004969
M3 - Article
C2 - 29352097
AN - SCOPUS:85050015295
VL - 90
SP - 309
EP - 311
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 7